计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Information
Fimasartan Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Targets
AT1 receptor
In vitro
Fimasartan is a selective AT1 receptor antagonist. The concentration that inhibits the binding of [125I]Ang II to the AT1 receptor from rat adrenal cortex by 50% (IC50) is 0.13 nM. Fimasartan shows superior inhibitory activity in the contraction of isolated rabbit thoracic aorta compared to other ARBs such as losartan and candesartan. Fimasartan potently attenuates myocardial apoptotic death in reperfused rat heart and H9c2 cells. Fimasartan could attenuate mitochondrial damage which is associated with minimizing the reduction in Bcl-2 and connected with the reduction in p53 and activation of Akt and GSK-3β, and inhibiting mitochondrial Ca2+ overload by suppressing the ICa,L and MCU.
In vivo
In various animal models including renal hypertensive rats, spontaneously hypertensive rats and Beagle dogs, fimasartan effectively reduces blood pressure in a dose-dependent manner following single or repeated oral and intravenous administration. Fimasartan does not affect general behavior, respiratory rate or tidal volume in experimental animals, and shows no adverse findings in the human ether-a-go-go-related gene (hERG) test or monkey telemetry study. A number of general toxicity, carcinogenic toxicity, genetic toxicity, and developmental toxicity studies given either orally or intravenously in various species including mice, rats, monkeys and dogs are conducted and these preclinical results demonstrate the safety and tolerability of fimasartan for long-term clinical use and offer sufficient safety margins to support the expected human therapeutic dose. Fimasartan is rapidly absorbed following oral administration with the time to peak plasma concentration (Tmax) ranging 0.5-3 h and the terminal half-life (t1/2) being 5-16 h at doses of 20 to 480 mg in healthy subjects. Similar results are obtained in patients with hypertension, i.e., Tmax ranges 0.5-1.3 h and t1/2 is 7-10 h following fimasartan administration at doses 20-180 mg in the subsequent phase II study. The urinary excretion of fimasartan is low, with the overall urinary excretion of unchanged drug over the first 24 h after dosing being less than 3% of the administered dose. Fimasartan undergoes nonrenal elimination with minimal metabolism. Fimasartan treatment before myocardial ischemia significantly attenuates reperfusion injury and apoptotic changes, possibly by suppressing mitochondrial damage during reperfusion. In various preclinical studies, including aortic balloon injury, myocardial infarct ischemia/reperfusion, doxorubicin cardiotoxicity, and ischemic stroke models, fimasartan shows anti-inflammatory and organ-protecting effects.
Cell Research(from reference)
Cell lines：H9c2 cells
Concentrations：50 μM
Incubation Time：24 h
规格
别名
非马沙坦
英文别名
2-((2-BUTYL-4-METHYL-6-OXO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-1,6-DIHYDROPYRIMIDIN-5-YL))-N,N-DIMETHYLTHIOACETAMIDE | 5-Pyrimidineethanethioamide, 2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
规格或纯度
10mM in DMSO
英文名称
Fimasartan
生化机理
非马沙坦（卡那布）是一种非肽类血管紧张素 II 受体拮抗剂（ARB），与 AT1 受体具有非竞争性、不可克服的结合力。它用于治疗高血压和心力衰竭。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
拮抗剂
作用机制
1 型血管紧张素 II 受体拮抗剂
名称和识别符
PubChem SID
分子类型
小分子
IUPAC Name
2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide
INCHI
1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)
InChi Key
AMEROGPZOLAFBN-UHFFFAOYSA-N
Smiles
CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C
Isomeric SMILES
CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C
分子量
501.65
Reaxy-Rn
26118944
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=26118944&ln=
技术文档
高级数据
系统学分类
分类树（Taxonomy Tree）
| 界（kingdom) | 有机化合物 |
|---|---|
| 超类（Superclass) | 苯类化合物 |
| 类（Class) | 苯及其取代衍生物 |
| 亚类（Subclass） | 联苯及其衍生物 |
| 中间层级节点（Intermediate Tree Nodes） | 暂无 |
| 直接上位类(Direct Parent) | 联苯及其衍生物 |
| 其他上位类（Alternative Parents） | 苯基四唑及其衍生物 嘧啶酮类 氢化嘧啶 硫代酰胺 杂芳族化合物 内酰胺类 硫代羧酸酰胺 氮杂环化合物 硫代羰基化合物 有机光子化合物 有机氧化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架（Molecular Framework) | 芳香族杂单环化合物 |
| 取代基（Substituents） | 芳香族杂单环化合物 - 氮杂环 - 吡唑 - 联苯 - 杂芳香族化合物 - 烃衍生物 - 羟吡啶 - 肟 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 有机硫化合物 - 苯基吡唑 - 嘧啶 - 嘧啶酮 - 四唑 - 硫酰胺 - 硫代羰基基团 - 硫代羧酸酰胺 |
| 描述（Description） | 该化合物属于联苯及其衍生物类有机化合物。这类化合物含有两个通过C-C键连接的苯环。 |
| 外部描述符（External Descriptors） | 暂无 |
三维结构
交互式化学结构模型
产品属性
| ALogP | 3.5 |
|---|
关联靶点（人）
AGTR1
Tclin
1型血管紧张素II受体(Type-1 angiotensin II receptor)
(1 活性数据)
AGTR1
Tclin
Type-1 angiotensin II receptor
(5176 活性数据)
PPARG
Tclin
Peroxisome proliferator-activated receptor gamma
(15191 活性数据)
关联靶点（其它种属）
Hdac6
Histone deacetylase 6 (222 活性数据)
AGTR1
Angiotensin II type 1a (AT-1a) receptor (440 活性数据)
Mus musculus (284745 活性数据)
Rattus norvegicus (775804 活性数据)
rep
Replicase polyprotein 1ab (378 活性数据)
SARS-CoV-2 (38078 活性数据)
作用机制
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
化学和物理性质
分子量
501.600 g/mol
XLogP3
3.500
氢键供体数Hydrogen Bond Donor Count
1
氢键受体数Hydrogen Bond Acceptor Count
6
可旋转键计数Rotatable Bond Count
9
精确质量Exact Mass
501.231 Da
单同位素质量Monoisotopic Mass
501.231 Da
拓扑极表面积Topological Polar Surface Area
122.000 Ų
重原子数Heavy Atom Count
36
形式电荷Formal Charge
0
复杂度Complexity
849.000
同位素原子数Isotope Atom Count
0
定义的原子立体中心计数Defined Atom Stereocenter Count
0
未定义的原子立体中心计数Undefined Atom Stereocenter Count
0
定义的键立体中心计数Defined Bond Stereocenter Count
0
未定义的键立体中心计数Undefined Bond Stereocenter Count
0
所有立体化学键的总数The total count of all stereochemical bonds
0
共价键合单元计数Covalently-Bonded Unit Count
1
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）